Recombinant rabies virus as potential live-viral vaccines for HIV-1.
Publication/Presentation Date
3-28-2000
Abstract
Recombinant, replication-competent rabies virus (RV) vaccine strain-based vectors were developed expressing HIV type I (HIV-1) envelope glycoprotein (gp160) from both a laboratory-adapted (CXCR4-tropic) and a primary (dual-tropic) HIV-1 isolate. An additional transcription stop/start unit within the RV genome was used to express HIV-1 gp160 in addition to the other RV proteins. The HIV-1 gp160 protein was stably and functionally expressed, as indicated by fusion of human T cell lines after infection with the recombinant RVs. Inoculation of mice with the recombinant RVs expressing HIV-1 gp160 induced a strong humoral response directed against the HIV-1 envelope protein after a single boost with recombinant HIV-1 gp120 protein. Moreover, high neutralization titers up to 1:800 against HIV-1 could be detected in the mouse sera. These data indicate that a live recombinant RV, a rhabdovirus, expressing HIV-1 gp160 may serve as an effective vector for an HIV-1 vaccine.
Volume
97
Issue
7
First Page
3544
Last Page
3549
ISSN
0027-8424
Published In/Presented At
Schnell, M. J., Foley, H. D., Siler, C. A., McGettigan, J. P., Dietzschold, B., & Pomerantz, R. J. (2000). Recombinant rabies virus as potential live-viral vaccines for HIV-1. Proceedings of the National Academy of Sciences of the United States of America, 97(7), 3544–3549. https://doi.org/10.1073/pnas.97.7.3544
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
10706640
Department(s)
Administration and Leadership
Document Type
Article